Reska Biotech

Reska Biotech Liabilities

The The Liabilities of Reska Biotech (GWIN) as of Nov 16, 2026 is 99,438.00 USD. In the previous year, The Liabilities was 114,106.00 USD — a change of -12.85% (lower).

Liabilities

99,438.00USD

YoY

-12.85%

Last updated:

In 2022, Reska Biotech's total liabilities amounted to 99,438.00 USD, a -12.85% difference from the 114,106.00 USD total liabilities in the previous year.

The Reska Biotech Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2014
17,000.00 USD
Jan 1, 2015
766,000.00 USD
Jan 1, 2016
33,263.00 USD
Jan 1, 2017
99,438.00 USD
Jan 1, 2018
114,106.00 USD
Jan 1, 2022
99,438.00 USD
The Reska Biotech Liabilities history
YEARLiabilitiesYoY
99,438.00USD-12.85%
114,106.00USD+14.75%
99,438.00USD+198.94%
33,263.00USD-95.66%
766,000.00USD+4,405.88%
17,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Reska Biotech Stock analysis

What does Reska Biotech do? The Glorywin Entertainment Group Inc is a Hong Kong-based company that specializes in the production, management, and marketing of entertainment content. The company was founded in 2005 and has been listed on the Canadian stock exchange since 2015. Glorywin's business model is based on the production and marketing of entertainment content in various sectors. This includes film and television production, music labels, event management, as well as the management and marketing of artists and celebrities. Over the years, the company has developed and produced a variety of products. In the film and television sector, these include TV series such as "The Four Detective Guards," "Journey to the East," "Ten Deadly Sins," and "Saviors in the Forbidden City." In addition, Glorywin has also produced films for the cinema such as "The Four," "Kung Fu Angels," and "The White Storm." Musically, the company is primarily active in the Asian pop industry and operates its own label with well-known artists such as Coco Lee and Janice Vidal. Another important business area for Glorywin is event management. The company organizes concerts, festivals, and other events in China and other Asian countries. The most well-known events include the "MTV Super Summit," the "Pepsi Music Festival," and the "Hong Kong Asian-Pop Music Festival." Glorywin often collaborates with other companies to reach a wider audience. In addition to the production of entertainment content and event management, Glorywin also operates its own leisure facilities. The goal is to make the brand and products of the company accessible to a broader audience. The company primarily focuses on theme parks and interactive museums. Currently, Glorywin operates the "Three Kingdoms City" theme park in China and the "Cool & Ice World" museum in Hong Kong. In recent years, the company has also focused on the digital media sector. Glorywin operates its own social media platform for fans and has developed a chatbot system for interactive communication with customers. The goal is to position and market the brand and products even more strongly in the digital world. To coordinate and manage all these activities, Glorywin has built an experienced team of managers and producers. The company works closely with international partners and collaborators to develop innovative products and events that excite the audience and tap into new markets. Overall, the company has become an important player in the Asian entertainment industry in recent years and has achieved numerous successes. This success is supported by the increasing popularity of Asian pop music, TV series, and films worldwide. In the future, Glorywin will likely continue to focus on these trends and attempt to establish itself in new markets. Reska Biotech is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Reska Biotech's Liabilities

Reska Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Reska Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Reska Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Reska Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Reska Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Reska Biotech stock

The Liabilities of Reska Biotech is 99,438.00 USD in 2022.

The Liabilities of Reska Biotech changed from 114,106.00 USD to 99,438.00 USD, representing a -12.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Reska Biotech since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Reska Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Reska Biotech

All Key Metrics — Reska Biotech